Folks who take Ozempic or Wegovy for diabetes and weight loss need not worry about a higher risk of suicidal thoughts or feelings while on the medications, a new, large review finds. In the study, which was funded by the U.S. National Institutes of Health, researchers turned to a database of more than 100 million patient records to measure the risks of suicidal ideation among people using semaglutide, which is sold as Ozempic for type 2 diabetes and Wegovy for weight loss. The results were published Jan. 5 in the journal Nature Medicine. Study author Dr. Rong Xu, a professor of biomedical informatics at Case Western Reserve University School of Medicine in Cleveland, told CNN that she decided to look into the issue after European regulators opened a probe into semaglutide and reports of suicidal thoughts last summer. Just this week, a quarterly report from the U.S. Food and Drug Administration revealed that the agency is looking into similar reports among users of multiple weight-loss drugs, including Ozempic and Wegovy. For the new review, Xu and her team, which included National Institute on Drug Abuse Director Dr. Nora Volkow, compared cases of suicidal ideation among people taking semaglutide with those taking other medicines for weight loss or diabetes. “We observed a lower incidence of suicidal ideations in patients who had taken semaglutide than in patients who were treated with non-GLP1R-targeting… read on > read on >

















